# Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule

> **NCT01641991** · PHASE4 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 328 (actual)

## Conditions studied

- Bacillus Anthracis (Anthrax)

## Interventions

- **BIOLOGICAL:** BioThrax®
- **BIOLOGICAL:** BioThrax®

## Key facts

- **NCT ID:** NCT01641991
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2013-03
- **Final completion:** 2013-06
- **Target enrollment:** 328 (ACTUAL)
- **Last updated:** 2014-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01641991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01641991, "Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01641991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*